<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-5-101</article-id><article-id pub-id-type="pmid">16095531</article-id><article-id pub-id-type="doi">10.1186/1471-2407-5-101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Mesquita</surname><given-names>B&#x000e1;rbara</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>barbara-mesquita@portugalmail.pt</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Veiga</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>isabelveiga@hotmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Pereira</surname><given-names>Deolinda</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>dpereira@ipoporto.min-saude.pt</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tavares</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>genetica@ipoporto.min-saude.pt</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Pinto</surname><given-names>Isabel M</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>implaboratorio@mail.telepac.pt</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Pinto</surname><given-names>Carla</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>carlapinto@portugalmail.pt</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Teixeira</surname><given-names>Manuel R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mteixeir@ipoporto.min-saude.pt</email></contrib><contrib id="A8" corresp="yes" contrib-type="author"><name><surname>Castedo</surname><given-names>S&#x000e9;rgio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>genetica@ipoporto.min-saude.pt</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Genetics, Portuguese Oncology Institute, 4200-072 Porto, Portugal</aff><aff id="I2"><label>2</label>Department of Medical Oncology, Portuguese Oncology Institute, 4200-072 Porto, Portugal</aff><aff id="I3"><label>3</label>Department of Pathology, Portuguese Oncology Institute, 4200-072 Porto, Portugal</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>11</day><month>8</month><year>2005</year></pub-date><volume>5</volume><fpage>101</fpage><lpage>101</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/101"/><history><date date-type="received"><day>26</day><month>4</month><year>2005</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2005</year></date></history><copyright-statement>Copyright &#x000a9; 2005 Mesquita et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether <italic>TUBB </italic>mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance.</p></sec><sec sec-type="methods"><title>Methods</title><p>Thirty-four patients with primary ovarian carcinomas (26 serous and eight clear cell carcinomas) treated with paclitaxel/cisplatin were analysed. <italic>TUBB </italic>exon 4 was analysed by nested PCR after a first round PCR using intronic primers. Microsatellite analysis was performed with the quasimonomorphic markers BAT 26 and BAT 34.</p></sec><sec><title>Results</title><p>Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours). Sequence analysis did not find any mutation in <italic>TUBB </italic>exon 4. Microsatellite instability was not detected in any of the ovarian carcinomas.</p></sec><sec><title>Conclusion</title><p>We conclude that <italic>TUBB </italic>exon 4 mutations and mismatch repair defects do not play a significant role in paclitaxel/cisplatin resistance.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Ovarian cancer is the fourth most common cancer in women [<xref ref-type="bibr" rid="B1">1</xref>]. The standard treatment for ovarian cancer is cytoreductive surgery followed by combination systemic chemotherapy [<xref ref-type="bibr" rid="B2">2</xref>]. Since the middle 90's, the combination paclitaxel/cisplatin became the standard chemotherapeutic treatment for poor prognosis ovarian cancer [<xref ref-type="bibr" rid="B3">3</xref>]. Nevertheless, some patients are resistant to this chemotherapeutic treatment, making it important to clarify the underlying mechanisms of resistance [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Paclitaxel binds to microtubules and causes kinetic suppression (stabilisation) of microtubule dynamics, promoting their polymerisation and cell cycle arrest in mitosis (antimitotic activity), which probably leads to apoptosis [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Microtubules are composed of a dimeric protein, tubulin, with alpha (&#x003b1;) and beta (&#x003b2;) tubulin heterodimers in dynamic equilibrium. The &#x003b2;-tubulin gene (<italic>TUBB</italic>), mapped to 6p21.3 [<xref ref-type="bibr" rid="B7">7</xref>], is composed of four exons and encodes a 445-aminoacid protein with GTPase function to which paclitaxel preferentially binds [<xref ref-type="bibr" rid="B8">8</xref>]. Cisplatin is activated intracellularly and establishes inter- and intra-strand DNA adducts that block replication and translation. The fate of cells after cisplatin exposure depends both on the extent of DNA damage and the cellular response to it, and apoptosis can be induced as a consequence [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Although the specific mechanism that triggers apoptosis is not totally clear, some evidence suggests that this process can be mediated by the DNA mismatch repair system (MMR) [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Drug resistance is considered a multifactorial process, but the detailed mechanisms are still unknown. Recently, point mutations in the &#x003b2;-tubulin gene, predominantly in exon 4, were associated with resistance to paclitaxel [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. Resistance to cisplatin was linked with anomalies in the DNA MMR system resulting in microsatellite instability (MSI) [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. In order to evaluate the relevance of these mechanisms to ovarian cancer chemoresistance, we screened <italic>TUBB </italic>exon 4 for mutations and performed MSI analysis in 34 ovarian carcinomas treated with paclitaxel/cisplatin and evaluated patients' response to chemotherapy.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient data</title><p>Thirty-four primary ovarian carcinoma patients, of serous (26 cases) or clear cell (eight cases) histological types (invasive or borderline), consecutively admitted at the Portuguese Oncology Institute &#x02013; Porto and treated with the adjuvant chemotherapy scheme paclitaxel/cisplatin, were analysed. Patients previously treated with other chemotherapeutic regimens or radiotherapy were excluded from the study.</p><p>Evaluation of treatment responses was done by an oncologist using computerized tomography or magnetic resonance and CA125 quantification, according to international guidelines [<xref ref-type="bibr" rid="B17">17</xref>]. Investigators performing laboratory analysis were not aware of chemotherapy response or resistance until the study was completed.</p></sec><sec><title>DNA extraction</title><p>Genomic DNA was extracted from chemo-na&#x000ef;ve, paraffin embedded tumours, after dissection. Tissue blocks were sectioned, mounted on glass slides, deparaffinised, and stained with haematoxylin and eosin. Tumour areas were identified under the microscope on each slide and marked. Areas with at least 70% of cancer cells were identified on tissue sections. Selected paraffin blocks were sectioned (5&#x003bc;m sections) and mounted in microscope slides. Marked tumour areas were selected with a sterile razor blade. Three sections of tissue were incubated in a solution of 10 mM Tris-HCl buffer (pH 8.0), 2.5 mM MgCl<sub>2</sub>, 50 mM KCl, 0.5% (p/v) Tween 20, and 1 mg/mL proteinase K for 48 hours at 55&#x000b0;C.</p></sec><sec><title><italic>TUBB </italic>exon 4 sequencing</title><p>For polymerase chain reaction (PCR) assays, different sets of oligonucleotides were designed to amplify specific regions of <italic>TUBB </italic>exon 4 that code for the GTP and paclitaxel binding sites. To assure that the amplicon was not a pseudogene, the following intronic primer set was used in the first round PCR: 5'AAG-GAG-ATA-CAT-CCG-AGG-GAA-TT3' and 5'AAG-GTA-TTC-ATG-ATG-CGA3'. After checking for first round PCR product in an agarose gel, a 1:10 dilution was used for nested PCRs with the following primers: set 1, 5'AGA-GAG-CTG-TGA-CTG-CCT-G3' and 5'AAG-GTA-TTC-ATG-ATG-CGA3'; set 2, 5'GCT-CTG-GAA-TGG-GCA-CTC3' and 5'CCG-TAG-GTT-GGT-TGT-GGT-CA3'; set 3, 5'CGG-GGA-TCT-GAA-CCA-CCT-T3' and 5'GAG-TGT-CAC-GGC-CTG-GAG-T3'. The PCR products were separated by electrophoresis in agarose gels stained with ethidium bromide and analysed in a transiluminator. All DNA samples were analysed in an automatic DNA sequencer ABI PRISM 310&#x02122; Genetic Analyser. The sequences were compared with the genomic sequence GenBank <ext-link ext-link-type="gen" xlink:href="AF070600">AF070600</ext-link>.</p></sec><sec><title>MSI evaluation</title><p>For microsatellite analysis, tumour DNA was amplified with primers for two quasimonomorphic markers BAT 26 (5'GAG-TGT-CAC-GGC-CTG-GAG-T3'; 5'AAC-CAT-TCA-ACA-TTT-TTA-ACC-C3') and BAT 34 (5'ACC-CTG-GAG-GAT-TTC-ATC-TC3'; 5'AAC-AAA-GCG-AGA-CCC-AGT-CT3') [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Fragments were analysed in an ABI PRISM 310&#x02122; Genetic Analyser.</p></sec></sec><sec><title>Results</title><p>Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours) (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>Amplicons of 700 bp were observed for all cases after amplification with the intronic primers (data not shown). Nested PCR with primer sets 1&#x02013;3 specific for <italic>TUBB </italic>exon 4 resulted in amplicons with 129, 254, and 201 bp, respectively (Figure <xref ref-type="fig" rid="F1">1</xref>). Sequencing analysis of all 34 cases showed no <italic>TUBB </italic>exon 4 mutations (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><p>Microsatellite analysis with markers BAT 26 and BAT 34 (Figure <xref ref-type="fig" rid="F3">3</xref>) showed the normal pattern in all cases, so no evidence for microsatellite instability was detected in this series.</p></sec><sec><title>Discussion</title><p>Tumour resistance to chemotherapy or disease relapses resistant to further treatment after an initial response are common events in current cytotoxic cancer treatment regimens [<xref ref-type="bibr" rid="B5">5</xref>]. With regard to ovarian cancer chemotherapy, the current major challenge is to understand why histologically similar tumours behave so differently when treated with the same chemotherapeutic regimen. The action of a drug potentially depends on several mechanisms, namely, metabolisation, access into the tumour microenvironment, intracellular uptake, interaction with the target, and subsequent signalling events [<xref ref-type="bibr" rid="B5">5</xref>]. It is therefore important to study the different molecular mechanisms that can be involved in chemotherapy resistance.</p><p>The rationale for studying the relationship between <italic>TUBB </italic>gene mutations with paclitaxel resistance came from the studies of Giannakakou <italic>et al </italic>and Gonzalez-Garay <italic>et al </italic>[<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>], who found <italic>TUBB </italic>mutations in ovarian cancer cell lines and in hamster cells, respectively. Subsequently, Monz&#x000f3; <italic>et al </italic>[<xref ref-type="bibr" rid="B12">12</xref>] reported <italic>TUBB </italic>mutations in 16 out of 36 (44.4%) paclitaxel resistant tumour samples from patients with advanced non-small cell lung cancer and proposed that <italic>TUBB </italic>mutations could represent a possible mechanism of paclitaxel resistance in that tumour type.</p><p>However, our findings in the present study argue against a significant role of <italic>TUBB </italic>gene mutations in paclitaxel resistance in ovarian cancer. In keeping with our results, Sale <italic>et al </italic>[<xref ref-type="bibr" rid="B22">22</xref>] and Lamendola <italic>et al </italic>[<xref ref-type="bibr" rid="B23">23</xref>] did not detect <italic>TUBB </italic>gene mutations in ovarian cancer samples. Similar findings have recently been obtained for several other tumour types, namely, lung [<xref ref-type="bibr" rid="B24">24</xref>], breast [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>], and gastric cancer [<xref ref-type="bibr" rid="B27">27</xref>]. Taken together, our and several other investigations concur that <italic>TUBB </italic>exon 4 mutations are not an important mechanism underlying paclitaxel resistance. To explain the early findings of Monz&#x000f3; <italic>et al </italic>[<xref ref-type="bibr" rid="B12">12</xref>], which were not reproduced by other authors, including the present study, Kelley <italic>et al </italic>[<xref ref-type="bibr" rid="B24">24</xref>] suggested that the primers used by Monz&#x000f3; <italic>et al </italic>[<xref ref-type="bibr" rid="B12">12</xref>] did not allow to discriminate <italic>TUBB </italic>from its pseudogenes [<xref ref-type="bibr" rid="B24">24</xref>]. Furthermore, the first studies reporting <italic>TUBB </italic>gene mutations were made in hamster cells [<xref ref-type="bibr" rid="B11">11</xref>] and in ovarian cancer cell lines [<xref ref-type="bibr" rid="B10">10</xref>] after selection by paclitaxel exposure, something that makes difficult a direct extrapolation of these findings to human tumours.</p><p>We have also evaluated the MSI status of the 34 ovarian carcinomas with quasimonomorphic BAT 26 and BAT 34 markers, but did not find any microsatellite unstable tumours. Some authors have described an association between cisplatin resistance and MMR system anomalies in ovarian adenocarcinomas [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>], as well as in colon cancer cell lines [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>]. Additionally, other studies found MSI in ovarian cancer, namely, in serous and clear cell histological types [<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B40">40</xref>]. However, the frequency of MSI identified in those studies was quite low (0&#x02013;14.3%), which is in agreement with our findings. To completely rule out any relationship between deficient mismatch repair and cisplatin resistance, one would have to analyse more microsatellite markers in a larger series of tumours paired with normal DNA.</p></sec><sec><title>Conclusion</title><p>We conclude that, contrarily to earlier suggestions, <italic>TUBB </italic>exon 4 mutations and MMR defects are not major mechanisms underlying paclitaxel and/or cisplatin resistance in ovarian cancer. Further investigation on alternative mechanisms of resistance to these drugs is warranted. Possible mechanisms to paclitaxel resistance are <italic>P-glycoprotein </italic>overexpression [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B41">41</xref>], differential &#x003b2;-tubulin isotype expression [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>], and apoptosis deregulation [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B44">44</xref>-<xref ref-type="bibr" rid="B46">46</xref>]. Decrease in intracellular cisplatin level, increase of tolerance or repair of DNA lesions, and alterations in the apoptotic cascade have also been related with cisplatin resistance [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B47">47</xref>]. These studies are necessary to predict individual response of patients to these chemotherapeutic agents.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>BM carried out the molecular genetic studies and drafted the manuscript. IV participated in the design of the study and coordination. DP was responsible for clinical surveillance. AS was responsible for paraffin slides. IMP was responsible for the histopathologic analysis. CP carried out sequence alignment. MT coordinated the study. SC conceived the study and participated in its design and coordination.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/101/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank the Portuguese Health Ministry for the financial support (Project nr. 191/99). B. Mesquita was a fellow of Funda&#x000e7;&#x000e3;o para Ci&#x000ea;ncia e Tecnologia. We thank Mariano Monz&#x000f3; and collaborators for useful discussions during this work.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>FI</given-names></name><name><surname>Devesa</surname><given-names>SS</given-names></name></person-group><article-title>Cancer burden in the year 2000: the global picture</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><fpage>S4</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">11602373</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(01)00267-2</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crown</surname><given-names>J</given-names></name><name><surname>O'Leary</surname><given-names>M</given-names></name></person-group><article-title>The taxanes: an update</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1176</fpage><lpage>1178</lpage><pub-id pub-id-type="pmid">10791395</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02074-2</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Bertelsen</surname><given-names>K</given-names></name><name><surname>James</surname><given-names>K</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Mangioni</surname><given-names>C</given-names></name><name><surname>Simonsen</surname><given-names>E</given-names></name><name><surname>Stuert</surname><given-names>G</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Vargote</surname><given-names>I</given-names></name><name><surname>Blom</surname><given-names>R</given-names></name><name><surname>Grimshaw</surname><given-names>R</given-names></name><name><surname>Atkinson</surname><given-names>RJ</given-names></name><name><surname>Swenerton</surname><given-names>KD</given-names></name><name><surname>Trope</surname><given-names>C</given-names></name><name><surname>Nardi</surname><given-names>M</given-names></name><name><surname>Kaern</surname><given-names>J</given-names></name><name><surname>Tumolo</surname><given-names>S</given-names></name><name><surname>Timmers</surname><given-names>P</given-names></name><name><surname>Roy</surname><given-names>JA</given-names></name><name><surname>Lhoas</surname><given-names>F</given-names></name><name><surname>Lindvall</surname><given-names>B</given-names></name><name><surname>Bacon</surname><given-names>M</given-names></name><name><surname>Birt</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>JE</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Paul</surname><given-names>J</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Pecorelli</surname><given-names>S</given-names></name></person-group><article-title>Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>699</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">10793106</pub-id><pub-id pub-id-type="doi">10.1093/jnci/92.9.699</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names/></name><name><surname>Ozols</surname><given-names>RF</given-names></name></person-group><article-title>Chemotherapy in advanced ovarian cancer</article-title><source>Semin Oncol</source><year>1998</year><volume>25</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">9633846</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Kaye</surname><given-names>SB</given-names></name></person-group><article-title>Ovarian cancer: strategies for overcoming resistance to chemotherapy</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>502</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">12835670</pub-id><pub-id pub-id-type="doi">10.1038/nrc1123</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TH</given-names></name><name><surname>Wang</surname><given-names>HS</given-names></name><name><surname>Soong</surname><given-names>YK</given-names></name></person-group><article-title>Paclitaxel-induced cell death: where the cell cycle and apoptosis come together</article-title><source>Cancer</source><year>2000</year><volume>88</volume><fpage>2619</fpage><lpage>2628</lpage><pub-id pub-id-type="pmid">10861441</pub-id><pub-id pub-id-type="doi">10.1002/1097-0142(20000601)88:11&#x0003c;2619::AID-CNCR26&#x0003e;3.0.CO;2-J</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Floyd-Smith</surname><given-names>GA</given-names></name><name><surname>de Martinville</surname><given-names>B</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name></person-group><article-title>An expressed tubulin gene, TUBB, is located on the short arm of human chromosome 6 and two related sequences are dispersed on chromosome 8 and 13</article-title><source>Exp Cell Res</source><year>1986</year><volume>163</volume><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">3007184</pub-id><pub-id pub-id-type="doi">10.1016/0014-4827(86)90084-4</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludue&#x000f1;a</surname><given-names>RF</given-names></name></person-group><article-title>Multiple forms of tubulin: different gene products and covalent modifications</article-title><source>Int Rev Cytol</source><year>1998</year><volume>178</volume><fpage>207</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">9348671</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>RP</given-names></name></person-group><article-title>Cellular and molecular determinants of cisplatin resistance</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>1535</fpage><lpage>1542</lpage><pub-id pub-id-type="pmid">9893624</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(98)00227-5</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giannakakou</surname><given-names>P</given-names></name><name><surname>Sackett</surname><given-names>DL</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Zhan</surname><given-names>Z</given-names></name><name><surname>Butters</surname><given-names>JT</given-names></name><name><surname>Fojo</surname><given-names>T</given-names></name><name><surname>Poruchynsky</surname><given-names>MS</given-names></name></person-group><article-title>Paclitaxel-resistant human ovarian cancer cells have mutant &#x003b2;-tubulins that exhibit impaired paclitaxel-driven polymerization</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>17118</fpage><lpage>17125</lpage><pub-id pub-id-type="pmid">9202030</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.27.17118</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Garay</surname><given-names>ML</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Blade</surname><given-names>K</given-names></name><name><surname>Menick</surname><given-names>DR</given-names></name><name><surname>Cabral</surname><given-names>F</given-names></name></person-group><article-title>A &#x003b2;-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance</article-title><source>J Biol Chem</source><year>1999</year><volume>271</volume><fpage>23875</fpage><lpage>23882</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.34.23875</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monz&#x000f3;</surname><given-names>M</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Sanch&#x000e9;z</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>O'Brate</surname><given-names>A</given-names></name><name><surname>Gonzalez-Larriba</surname><given-names>JL</given-names></name><name><surname>Alberola</surname><given-names>V</given-names></name><name><surname>Lorenzo</surname><given-names>JC</given-names></name><name><surname>Nunez</surname><given-names>L</given-names></name><name><surname>Ro</surname><given-names>JY</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name></person-group><article-title>Paclitaxel resistance in non-small cell lung cancer associated with &#x003b2;-tubulin gene mutations</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1786</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">10561216</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de las Alas</surname><given-names>MM</given-names></name><name><surname>Aebi</surname><given-names>S</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Howell</surname><given-names>SB</given-names></name><name><surname>Los</surname><given-names>G</given-names></name></person-group><article-title>Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance</article-title><source>J Natl Cancer Inst</source><year>1997</year><volume>89</volume><fpage>1537</fpage><lpage>1541</lpage><pub-id pub-id-type="pmid">9337351</pub-id><pub-id pub-id-type="doi">10.1093/jnci/89.20.1537</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaurs</surname><given-names>C</given-names></name><name><surname>Bignon</surname><given-names>YJ</given-names></name></person-group><article-title>Quoi de neuf sur la signification des instabilit&#x000e9;s microssatellitaires dans les pathologies tumorales humaines?</article-title><source>Bull Cancer</source><year>1997</year><volume>84</volume><fpage>1061</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">9536988</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Aebi</surname><given-names>S</given-names></name><name><surname>Howell</surname><given-names>SB</given-names></name></person-group><article-title>The role of DNA mismatch repair in drug resistance</article-title><source>Clin Cancer Res</source><year>1998</year><volume>4</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9516945</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lage</surname><given-names>H</given-names></name><name><surname>Dietel</surname><given-names>M</given-names></name></person-group><article-title>Involvement of the DNA mismatch repair system in antineoplastic drug resistance</article-title><source>J Cancer Res Clin Oncol</source><year>1999</year><volume>125</volume><fpage>156</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">10235469</pub-id><pub-id pub-id-type="doi">10.1007/s004320050258</pub-id></citation></ref><ref id="B17"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Soignet</surname><given-names>SL</given-names></name><name><surname>Spriggs</surname><given-names>DR</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Barakat RR, Bevers MW, Gershenson DM</surname></name></person-group><article-title>General principles of chemotherapy</article-title><source>Handbook of Gynecologic Oncology</source><year>2001</year><publisher-name>London: Martin Dunitz</publisher-name><fpage>243</fpage><lpage>263</lpage></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname><given-names>JM</given-names></name><name><surname>Cottu</surname><given-names>PH</given-names></name><name><surname>Thuille</surname><given-names>B</given-names></name><name><surname>Salmon</surname><given-names>RJ</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Hamelin</surname><given-names>R</given-names></name></person-group><article-title>BAT &#x02013; 26, an indicator of the replication error phenotype in colorectal cancers and cell lines</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>300</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">9000572</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>XP</given-names></name><name><surname>Hoang</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Seruca</surname><given-names>R</given-names></name><name><surname>Carneiro</surname><given-names>F</given-names></name><name><surname>Sobrinho-Simoes</surname><given-names>M</given-names></name><name><surname>Lothe</surname><given-names>RA</given-names></name><name><surname>Gleeson</surname><given-names>CM</given-names></name><name><surname>Russel</surname><given-names>SE</given-names></name><name><surname>Muzeau</surname><given-names>F</given-names></name><name><surname>Flejou</surname><given-names>JF</given-names></name><name><surname>Hoang-Xuan</surname><given-names>L</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Hamelin</surname><given-names>R</given-names></name></person-group><article-title>Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites</article-title><source>Genes Chromosomes Cancer</source><year>1998</year><volume>21</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">9491320</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(199802)21:2&#x0003c;101::AID-GCC4&#x0003e;3.0.CO;2-4</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>P</given-names></name><name><surname>Crawford</surname><given-names>L</given-names></name></person-group><article-title>Characterization of the human P53 gene</article-title><source>Mol Cell Biol</source><year>1986</year><volume>6</volume><fpage>1379</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">2946935</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benedet</surname><given-names>JL</given-names></name><name><surname>Bender</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>H</given-names><suffix>III</suffix></name><name><surname>Ngan</surname><given-names>HYS</given-names></name><name><surname>Pecorelli</surname><given-names>S</given-names></name></person-group><article-title>FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology</article-title><source>Int J Gynaecol Obstet</source><year>2000</year><volume>70</volume><fpage>209</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">11041682</pub-id><pub-id pub-id-type="doi">10.1016/S0020-7292(00)90001-8</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sale</surname><given-names>S</given-names></name><name><surname>Sung</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Duran</surname><given-names>GE</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Fojo</surname><given-names>T</given-names></name><name><surname>Oefner</surname><given-names>PJ</given-names></name><name><surname>Sikic</surname><given-names>BI</given-names></name></person-group><article-title>Conservation of the class I &#x003b2;-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers</article-title><source>Mol Cancer Ther</source><year>2002</year><volume>1</volume><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">12467216</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamendola</surname><given-names>DE</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Penson</surname><given-names>RT</given-names></name><name><surname>Oliva</surname><given-names>E</given-names></name><name><surname>Seiden</surname><given-names>MV</given-names></name></person-group><article-title>Beta tubulin mutations are rare in ovarian carcinoma</article-title><source>Anticancer Res</source><year>2003</year><volume>23</volume><fpage>681</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">12680167</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>MJ</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Harpole</surname><given-names>DH</given-names></name></person-group><article-title>Genetic analysis of the &#x003b2;-tubulin gene, TUBB, in non-small-cell lung cancer</article-title><source>J Nat Cancer Inst</source><year>2001</year><volume>93</volume><fpage>1886</fpage><lpage>1888</lpage><pub-id pub-id-type="pmid">11752014</pub-id><pub-id pub-id-type="doi">10.1093/jnci/93.24.1886</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Miyoshi</surname><given-names>Y</given-names></name><name><surname>Egawa</surname><given-names>C</given-names></name><name><surname>Ishitobi</surname><given-names>M</given-names></name><name><surname>Tamaki</surname><given-names>Y</given-names></name><name><surname>Monden</surname><given-names>M</given-names></name><name><surname>Nogushi</surname><given-names>S</given-names></name></person-group><article-title>Mutational analysis of the class I beta-tubulin gene in human breast cancer</article-title><source>Int J Cancer</source><year>2002</year><volume>101</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12209587</pub-id><pub-id pub-id-type="doi">10.1002/ijc.10575</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeno</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Hama</surname><given-names>Y</given-names></name><name><surname>Shingu</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Nakagomi</surname><given-names>H</given-names></name><name><surname>Tsuchiaya</surname><given-names>S</given-names></name><name><surname>Fujimori</surname><given-names>M</given-names></name></person-group><article-title>Mutation of the class I &#x003b2;-tubulin gene does not predict response to paclitaxel for breast cancer</article-title><source>Cancer Lett</source><year>2003</year><volume>198</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">12893435</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3835(03)00279-9</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urano</surname><given-names>N</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Miyoshi</surname><given-names>Y</given-names></name><name><surname>Nogushi</surname><given-names>S</given-names></name><name><surname>Takiguchi</surname><given-names>S</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Monden</surname><given-names>M</given-names></name></person-group><article-title>Absence of beta-tubulin gene mutation in gastric carcinoma</article-title><source>Gastric Cancer</source><year>2003</year><volume>6</volume><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">12861402</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orth</surname><given-names>K</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Gazdar</surname><given-names>A</given-names></name><name><surname>Bowcock</surname><given-names>A</given-names></name><name><surname>Mathis</surname><given-names>JM</given-names></name><name><surname>Sambrook</surname><given-names>J</given-names></name></person-group><article-title>Genetic instability in human ovarian cancer cell lines</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>9495</fpage><lpage>9499</lpage><pub-id pub-id-type="pmid">7937795</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aebi</surname><given-names>S</given-names></name><name><surname>Haidar</surname><given-names>BK</given-names></name><name><surname>Gordon</surname><given-names>R</given-names></name><name><surname>Cenni</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Christen</surname><given-names>RD</given-names></name><name><surname>Boland</surname><given-names>CR</given-names></name><name><surname>Koi</surname><given-names>M</given-names></name><name><surname>Fishel</surname><given-names>R</given-names></name><name><surname>Howell</surname><given-names>SB</given-names></name></person-group><article-title>Loss of DNA mismatch repair in acquired resistance to cisplatin</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>3087</fpage><lpage>3090</lpage><pub-id pub-id-type="pmid">8674066</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Nebel</surname><given-names>S</given-names></name><name><surname>Norris</surname><given-names>PS</given-names></name><name><surname>Baergen</surname><given-names>RN</given-names></name><name><surname>Wilczynski</surname><given-names>SP</given-names></name><name><surname>Costa</surname><given-names>MJ</given-names></name><name><surname>Haas</surname><given-names>M</given-names></name><name><surname>Cannistra</surname><given-names>SA</given-names></name><name><surname>Howell</surname><given-names>SB</given-names></name></person-group><article-title>Enrichment for DNA mismatch repair deficient cells during treatment with cisplatin</article-title><source>Int J Cancer</source><year>1998</year><volume>77</volume><fpage>741</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">9688308</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19980831)77:5&#x0003c;741::AID-IJC13&#x0003e;3.0.CO;2-4</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Nebel</surname><given-names>S</given-names></name><name><surname>Aebi</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Cenni</surname><given-names>B</given-names></name><name><surname>Nheme</surname><given-names>A</given-names></name><name><surname>Christen</surname><given-names>RD</given-names></name><name><surname>Howell</surname><given-names>SB</given-names></name></person-group><article-title>The role of DNA mismatch repair in platinum drug resistance</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>4881</fpage><lpage>4886</lpage><pub-id pub-id-type="pmid">8895738</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aebi</surname><given-names>S</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Gordon</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Finj</surname><given-names>JL</given-names></name><name><surname>Howell</surname><given-names>SB</given-names></name></person-group><article-title>Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>1763</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">9815561</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Nebel</surname><given-names>S</given-names></name><name><surname>Norris</surname><given-names>PS</given-names></name><name><surname>Aebi</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>TP</given-names></name><name><surname>Nehme</surname><given-names>A</given-names></name><name><surname>Christen</surname><given-names>RD</given-names></name><name><surname>Haas</surname><given-names>M</given-names></name><name><surname>MacLeod</surname><given-names>CL</given-names></name><name><surname>Howell</surname><given-names>SB</given-names></name></person-group><article-title><italic>In vitro </italic>and <italic>in vivo </italic>resistance to cisplatin in cells that have lost DNA mismatch repair</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>1841</fpage><lpage>1845</lpage><pub-id pub-id-type="pmid">9157971</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Enomoto</surname><given-names>T</given-names></name><name><surname>Yoshino</surname><given-names>K</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Buzard</surname><given-names>GS</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Okudaira</surname><given-names>Y</given-names></name></person-group><article-title>Microsatellite instability and alterations in the <italic>hMSH2 </italic>gene in human ovarian cancer</article-title><source>Int J Cancer</source><year>1995</year><volume>64</volume><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">8550235</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pieretti</surname><given-names>M</given-names></name><name><surname>Cavalieri</surname><given-names>C</given-names></name><name><surname>Conway</surname><given-names>PS</given-names></name><name><surname>Gallion</surname><given-names>HH</given-names></name><name><surname>Powell</surname><given-names>DE</given-names></name><name><surname>Turker</surname><given-names>MS</given-names></name></person-group><article-title>Genetic alterations distinguish different types of ovarian tumors</article-title><source>Int J Cancer</source><year>1995</year><volume>64</volume><fpage>434</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">8550247</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arzimanoglou</surname><given-names>II</given-names></name><name><surname>Lallas</surname><given-names>T</given-names></name><name><surname>Osborne</surname><given-names>M</given-names></name><name><surname>Barber</surname><given-names>H</given-names></name><name><surname>Gilbert</surname><given-names>F</given-names></name></person-group><article-title>Microsatellite instability differences between familial and sporadic ovarian cancers</article-title><source>Carcinogenesis</source><year>1996</year><volume>17</volume><fpage>1799</fpage><lpage>1804</lpage><pub-id pub-id-type="pmid">8824498</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>CJ</given-names></name><name><surname>Diebold</surname><given-names>J</given-names></name><name><surname>Hirschmann</surname><given-names>A</given-names></name><name><surname>Rohrbach</surname><given-names>H</given-names></name><name><surname>Schid</surname><given-names>S</given-names></name><name><surname>Lohrs</surname><given-names>U</given-names></name></person-group><article-title>Microsatellite analysis in serous tumors of the ovary</article-title><source>Int J Gynecol Pathol</source><year>1999</year><volume>18</volume><fpage>158</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">10202674</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geisler</surname><given-names>JP</given-names></name><name><surname>Goodheatr</surname><given-names>MJ</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Holmes</surname><given-names>RJ</given-names></name><name><surname>Hatterman-Zogg</surname><given-names>MA</given-names></name><name><surname>Buller</surname><given-names>RE</given-names></name></person-group><article-title>Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma</article-title><source>Cancer</source><year>2003</year><volume>98</volume><fpage>2199</fpage><lpage>2206</lpage><pub-id pub-id-type="pmid">14601090</pub-id><pub-id pub-id-type="doi">10.1002/cncr.11770</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>KQ</given-names></name><name><surname>Albarracin</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>D</given-names></name><name><surname>Zhong</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Luthra</surname><given-names>R</given-names></name><name><surname>Broaddus</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Microsatellite instability and alteration of the expression of the hMLH1 and hMSH2 in ovarian clear cell carcinoma</article-title><source>Hum Pathol</source><year>2004</year><volume>35</volume><fpage>552</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">15138928</pub-id><pub-id pub-id-type="doi">10.1016/j.humpath.2003.12.009</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>G</given-names></name><name><surname>Kallinowski</surname><given-names>T</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Dietmaier</surname><given-names>W</given-names></name><name><surname>Wild</surname><given-names>PJ</given-names></name><name><surname>Schraml</surname><given-names>P</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name></person-group><article-title>Different types of microsatellite instability in ovarian carcinoma</article-title><source>Int J Cancer</source><year>2004</year><volume>112</volume><fpage>643</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">15382045</pub-id><pub-id pub-id-type="doi">10.1002/ijc.20455</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parekh</surname><given-names>H</given-names></name><name><surname>Wiesen</surname><given-names>K</given-names></name><name><surname>Simpkins</surname><given-names>H</given-names></name></person-group><article-title>Acquisition of taxol resistance via P-glycoprotein and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells</article-title><source>Biochem Pharmacol</source><year>1997</year><volume>53</volume><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">9105396</pub-id><pub-id pub-id-type="doi">10.1016/S0006-2952(97)83383-7</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ranganathan</surname><given-names>S</given-names></name><name><surname>Benetatos</surname><given-names>CA</given-names></name><name><surname>Colarusso</surname><given-names>PJ</given-names></name><name><surname>Dexter</surname><given-names>DW</given-names></name><name><surname>Hudes</surname><given-names>GR</given-names></name></person-group><article-title>Altered &#x003b2;-tubulin isotype expression in paclitaxel resistant human prostate carcinoma cells</article-title><source>Brit J Cancer</source><year>1998</year><volume>77</volume><fpage>562</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">9484812</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kavallaris</surname><given-names>M</given-names></name><name><surname>Burkhart</surname><given-names>CA</given-names></name><name><surname>Horowitz</surname><given-names>SB</given-names></name></person-group><article-title>Antisense oligonucleotides to class III &#x003b2;-tubulin sensitize drug-resistant cells to Taxol</article-title><source>Brit J Cancer</source><year>1999</year><volume>80</volume><fpage>1020</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">10362110</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6690507</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haldar</surname><given-names>S</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Bcl2 is the guardian of microtubule integrity</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">9000560</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JR</given-names></name><name><surname>Fletcher</surname><given-names>B</given-names></name><name><surname>Page</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Nunez</surname><given-names>G</given-names></name><name><surname>Baker</surname><given-names>V</given-names></name></person-group><article-title>Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis</article-title><source>Gynecol Oncol</source><year>1998</year><volume>70</volume><fpage>398</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">9790794</pub-id><pub-id pub-id-type="doi">10.1006/gyno.1998.5125</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Niloff</surname><given-names>E</given-names></name><name><surname>Weisman</surname><given-names>C</given-names></name><name><surname>Strobel</surname><given-names>T</given-names></name><name><surname>Cannistra</surname><given-names>SH</given-names></name></person-group><article-title>BAX protein expression and clinical outcome in epithelial ovarian cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>2583</fpage><lpage>2590</lpage><pub-id pub-id-type="pmid">9704707</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perego</surname><given-names>P</given-names></name><name><surname>Romanelli</surname><given-names>S</given-names></name><name><surname>Carenini</surname><given-names>N</given-names></name><name><surname>Magnani</surname><given-names>I</given-names></name><name><surname>Leone</surname><given-names>R</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name><name><surname>Paolicchi</surname><given-names>A</given-names></name><name><surname>Zunino</surname><given-names>F</given-names></name></person-group><article-title>Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol</article-title><source>Ann Oncol</source><year>1998</year><volume>9</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">9636834</pub-id><pub-id pub-id-type="doi">10.1023/A:1008265012435</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Nested PCR products (in duplicate) obtained with the three primer sets specific for <italic>TUBB </italic>exon 4 in an ovarian carcinoma (from right to left, lane 1: 100 bp step ladder; lanes 2 and 3: 129 bp amplicon &#x02013; set 1 primers; lanes 4 and 5: 254 bp amplicon &#x02013; set 2 primers; lanes 6 and 7: 201 bp amplicon &#x02013; set 3 primers).</p></caption><graphic xlink:href="1471-2407-5-101-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Electrophorogram of part of <italic>TUBB </italic>exon 4 without any sequence variation in an ovarian carcinoma.</p></caption><graphic xlink:href="1471-2407-5-101-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Electrophorograms of BAT 26 (A) and BAT 34 (B) markers in an ovarian carcinoma, showing the same pattern found in normal control DNA.</p></caption><graphic xlink:href="1471-2407-5-101-3"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical, pathological and genetic data of 34 ovarian cancer patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold><italic>Patient</italic></bold></td><td align="center"><bold><italic>Histological type</italic></bold></td><td align="center"><bold><italic>Stage</italic></bold></td><td align="center"><bold><italic>Grade</italic></bold></td><td align="center"><bold><italic>Residual tumour</italic></bold></td><td align="center"><bold><italic>Treatment response</italic></bold></td><td align="center"><bold><italic>Exon 4 TUBB mutation</italic></bold></td><td align="center"><bold><italic>MSI status</italic></bold></td></tr></thead><tbody><tr><td align="center">1</td><td align="center">Serous</td><td align="center">III</td><td align="center">1</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">2</td><td align="center">Serous</td><td align="center">III</td><td align="center">2</td><td align="center">&#x0003c; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">3</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">4</td><td align="center">Serous</td><td align="center">III</td><td align="center">1</td><td align="center">&#x0003e; 2 cm</td><td align="center">WR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">5</td><td align="center">Serous</td><td align="center">III</td><td align="center">2</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">6</td><td align="center">Serous</td><td align="center">III</td><td align="center">2</td><td align="center">&#x0003c; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">7</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">8</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">9</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">10</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">11</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">12</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">WR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">13</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">WR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">14</td><td align="center">Serous</td><td align="center">IV</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">PR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">15</td><td align="center">Serous</td><td align="center">IV</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">16</td><td align="center">Serous</td><td align="center">IV</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">WR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">17</td><td align="center">Serous</td><td align="center">IV</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">WR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">18</td><td align="center">Serous</td><td align="center">IV</td><td align="center">3</td><td align="center">&#x0003c; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">19</td><td align="center">Serous</td><td align="center">I</td><td align="center">1</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">20</td><td align="center">Serous</td><td align="center">II</td><td align="center">3</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">21</td><td align="center">Serous</td><td align="center">III</td><td align="center">1</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">22</td><td align="center">Serous</td><td align="center">III</td><td align="center">3</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">23</td><td align="center">Serous</td><td align="center">III</td><td align="center">1</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">24</td><td align="center">Serous</td><td align="center">II</td><td align="center">B</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">25</td><td align="center">Serous</td><td align="center">II</td><td align="center">B</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">26</td><td align="center">Serous</td><td align="center">III</td><td align="center">B</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">27</td><td align="center">Clear cell</td><td align="center">I</td><td align="center">3</td><td align="center">&#x0003c; 2 cm</td><td align="center">CR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">28</td><td align="center">Clear cell</td><td align="center">II</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">WR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">29</td><td align="center">Clear cell</td><td align="center">III</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">PR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">30</td><td align="center">Clear cell</td><td align="center">IV</td><td align="center">3</td><td align="center">&#x0003e; 2 cm</td><td align="center">WR</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">31</td><td align="center">Clear cell</td><td align="center">I</td><td align="center">3</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">32</td><td align="center">Clear cell</td><td align="center">I</td><td align="center">3</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">33</td><td align="center">Clear cell</td><td align="center">II</td><td align="center">3</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr><tr><td align="center">34</td><td align="center">Clear cell</td><td align="center">III</td><td align="center">3</td><td align="center">Absent</td><td align="center">-</td><td align="center">Not present</td><td align="center">Stable</td></tr></tbody></table><table-wrap-foot><p>B: borderline tumours; CR: complete response; PR: partial response; WR: without response. The stage classification was according to the <italic>Federation Internationale de Gynecologie </italic>[21] and grading was defined as well differentiated (1), moderately differentiated (2), and poorly differentiated (3).</p></table-wrap-foot></table-wrap></sec></back></article> 